LivaNova (LIVN) Return on Capital Employed (2016 - 2026)
LivaNova (LIVN) reported Return on Capital Employed of 10.69% for Q1 2026, up 167.0% on a YoY basis from 4.0% in Q1 2025, and down 4.92% sequentially from 11.24% in Q4 2025.
LivaNova (LIVN) Return on Capital Employed (2016 - 2026) Analysis & Trends
LivaNova (LIVN) has 11 years of Return on Capital Employed data on file, last reported at 10.69% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 167.0% year-over-year to 10.69%; the trailing twelve-month figure through Mar 2026 stood at 10.69% (up 167.0% YoY), and the FY2025 full-year result was 11.41%, up 519.0% from the prior year.
- Return on Capital Employed declined to 10.69% in Q1 2026, from 11.24% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 11.37% in Q3 2025 to a low of 5.07% in Q2 2023.
- A 5-year average of 2.4% and a median of 0.72% in 2022 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed surged 2167 bps in 2022 and tumbled 897 bps in 2023, its largest moves.
- Tracing LIVN's Return on Capital Employed over 5 years: stood at 3.92% in 2022, then climbed by 15 bps to 3.35% in 2023, then soared by 282 bps to 6.08% in 2024, then jumped by 85 bps to 11.24% in 2025, then decreased by 5 bps to 10.69% in 2026.
- Business Quant data shows LIVN's Return on Capital Employed at 10.69% in Q1 2026, 11.24% in Q4 2025, and 11.37% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 9.61% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 12.24% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 8.02% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 9.62% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 11.13% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 24.24% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 8.38% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 9.30% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | LivaNova | 4.30 Bn | 3.76 Bn | 243.75 Mn | 10.69% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.69% |
| Dec 31, 2025 | 11.24% |
| Sep 30, 2025 | 11.37% |
| Jun 30, 2025 | 10.29% |
| Mar 31, 2025 | 9.01% |
| Dec 31, 2024 | 6.08% |
| Sep 30, 2024 | 0.30% |
| Jun 30, 2024 | -2.00% |
| Mar 31, 2024 | -2.36% |
| Dec 31, 2023 | -3.35% |
| Sep 30, 2023 | 1.64% |
| Jun 30, 2023 | -5.07% |
| Mar 31, 2023 | -4.48% |
| Dec 31, 2022 | -3.92% |
| Sep 30, 2022 | -3.32% |
| Jun 30, 2022 | 3.90% |
| Mar 31, 2022 | 0.72% |
| Dec 31, 2021 | -0.05% |
| Sep 30, 2021 | -16.73% |
| Jun 30, 2021 | -17.76% |